Modi govt seeks report from Karnataka, other states to extend ban on SIMI

Mangaluru, Feb 16: Leaving spectators awestruck, Karnataka's Srinivasa Gowda ran 142.5 meters in 13.62 seconds at traditional buffalo race Kambala, following which people started comparing him to former Jamaican Sprinter Usain Bolt.

Gowda, who is from Mudbidri town, accomplished the feat during a Kambala race in a paddy field in Kadri on February 1.

"People are comparing me to Usain Bolt. He is a world champion, I am only running in a slushy paddy field," said Srinivasa Gowda.

People took to social media and drew a parallel between him and Bolt. Twitterati hailed Gowda and his accomplishment on the muddy grounds.

Kambala is an annual buffalo race held in the southwestern state of Karnataka.

Traditionally, it is sponsored by local Tuluva landlords and households in the coastal districts of Dakshina Kannada and Udupi.

"I'll call Karnataka's Srinivasa Gowda for trials by top SAI Coaches. There's lack of knowledge in masses about the standards of Olympics especially in athletics where ultimate human strength & endurance are surpassed. I'll ensure that no talents in India is left out untested," Union Sports and Youth Affairs Minister Kiren Rijiju tweeted on Saturday.

Thrissur, Mar 7: A local temple in Kerala is at the centre of a social media storm after the picture of a ''Brahmins-only toilet'' outside its main campus went viral on online platforms, prompting the management to remove the signboard.

The picture of three toilets, with signboards showing "Men", "Women" and "Brahmins", at the Kuttumukku Mahadeva Temple in Thrissur, has gone viral with many social media users viewing it as an unethical practise that can portray the progressive state in a bad light.

However, temple officials said the toilets were located outside the main campus and the board was brought to their notice only now.

Kannan, an official of the temple committee, said the board was placed nearly two decades ago and nobody raised any complaint against it so far.

"That particular toilet was being used by priests and other temple employees. We didn't even notice that board... As soon as we came to know about it, we removed it and affixed a staff-only board," he told PTI.

Also a CPI-M functionary and ward councillor, Kannan said the shrine and it's management was against all kinds of unethical customs.

The temple official said they were planning to pursue legal measures against the man who posted the photo of the toilets on social media.

"We suspect that he did it deliberately to create issues during the time of the festival and to tarnish the shrine's reputation. Not only that, the photo he shared was an old one though he claimed that it was taken during the time of the festival, " he said.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.